Solid Biosciences Inc (SLDB)
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case
BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference
PMGC Holdings Inc. Announces Strategic Share Acquisition in Micro Modular Reactor (MMR) Focused Nuclear Energy Company, Nuclea Energy Inc.
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program